At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 4 enrolled
Drug / intervention
Grazoprevirdrug
Likely dose
Grazoprevir 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients
In Brief
A Phase 1 clinical trial evaluating Grazoprevir for Hepatitis C. Completed, enrolled 4 participants.
Detailed Summary
The goal of this study was to compare hepatic pharmacokinetics (PK) derived from liver tissue to plasma PK after administration of grazoprevir (MK-5172) to participants with chronic hepatitis C virus (HCV) infection. Participants will be randomized to one of four different liver ultrasound-guided Fine Needle Aspirate (FNA) schedules (at 4-, 8-, 24-, or 72-hours after the Day 7 dose).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartOct 2013
Primary CompletionJul 2014
TodayJul 2026
First PostedFeb 23, 2012
Enrollment StartOct 1, 2013
Primary CompletionJul 31, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.4 years ago
Interventions
Grazoprevirdrug
GZR 100 mg tablet by mouth q.d. for 7 days.